Hackensack University Medical Center Joins Impella ECP Pivotal Trial

World’s smallest heart pump technology support evaluated in high-risk PCI procedures

Hackensack University Medical Center recently joined the Impella ECP Pivotal Trial and enrolled its first patients. 

Interventional cardiologists Ankitkumar Patel, M.D., Haroon Faraz, M.D., and Pranaychandra Vaidya, M.D., successfully performed the center’s first 11 Impella ECP cases in the Hackensack University Medical Center cardiac catheterization lab. This experience places Hackensack as the second highest enroller in the world. The patients received the new Impella ECP, the world’s smallest heart pump technology support, during high-risk percutaneous coronary intervention (HRPCI) procedures.

This novel technology is a complete redesign of the Impella pump and is being evaluated for complex, high-risk PCI. Dr. Patel is serving as primary investigator, and Dr. Vaidya and Dr. Faraz are co-investigators. 

Male and female patients between 18 and 90 years of age were enrolled as part of the pivotal trial, which will ultimately enroll up to 256 patients who will receive Impella ECP support during an elective or urgent high-risk PCI.

This trial continues Hackensack University Medical Center’s status as a priority destination for the most significant new Impella device releases. The center is one of only three sites in New Jersey where physicians were trained in the new, much smaller 9f ECP device.

“Hackensack University Medical Center continues to be at the forefront of interventional cardiology care and academic research. As an interventional program, Dr. Vaidya, Dr. Faraz and I are committed to improving patient care and bringing novel technology and therapies,” Dr. Patel said.

Learn more about cardiovascular innovations happening at Hackensack University Medical Center.